Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Leonard Schleifer, the founder and CEO of Regeneron Pharmaceuticals, said on Sunday that President Trump's successful treatment with the company's antibody cocktail is "the weakest evidence you can get" on whether the drug is a cure.
Driving the news: Since leaving Walter Reed Medical Center on Monday, Trump has repeatedly claimed that he is "immune" from COVID-19 and said he views the antibody cocktail as a "cure."
What they're saying: “The president’s case is a case of one, and that’s what we call a case report. And it is evidence of what's happening, but it’s kind of the weakest evidence that you can get," Schleifer told CBS News' "Face the Nation."
- “[T]he real evidence about how good a drug is and what it will do on average has to come from these larger clinical trials, these randomized clinical trials, which are the gold standard, and those are ongoing," he said.
- The president’s case is “just low down on the evidence scale that we really need," and while the drug does create immunity, "it's probably going to last you for months," Schleifer added.
The bottom line: “Regeneron can’t do this alone. We need the entire industry. And I am so proud the industry has risen,” Schleifer said.
What to watch: Regeneron and Eli Lilly, which is developing a similar therapy, have applied for an emergency use authorization from the FDA.
Go deeper: Ex-FDA chief says Trump "definitely missed the window" to mass produce antibody drug